替罗非班联合尤瑞克林对急性进展性脑梗死患者有显著疗效
Significant effect of tirofiban combined with ureklin in the treatment of patients with APCI
陈玉涛 1刘秀君 1张瑞燕 1黄津 1王坤 1杜远生 1王丽丽1
作者信息
- 1. 邢台市第三医院神经内科,河北邢台 054000
- 折叠
摘要
目的:探讨替罗非班联合尤瑞克林治疗急性进展性脑梗死(APCI)患者的疗效,并分析其影响因素.方法:选择160例APCI患者,信封法随机分为观察组和对照组,各80例.对照组采取尤瑞克林治疗,观察组采取替罗非班联合尤瑞克林治疗.比较2组临床疗效、美国国立卫生研究院量表(NIHSS)评分、Barthel指数评定量表(BI)评分、Rankin修订量表评分(mRS)和不良反应.采用单因素分析及Logistic 回归分析影响患者疗效的危险因素.结果:观察组治疗有效率(92.50％vs 81.25％)、预后良好率(91.25％vs 80.00％)高于对照组(P均＜0.05).治疗后,2组患者的NIHSS评分明显降低,BI评分明显增加,且观察组患者治疗3、7、14 d的NIHSS评分、BI评分均优于对照组(P均＜0.05).2组患者不良反应发生率比较,差异无统计学意义(P＞0.05).单因素、多因素Logistic 回归分析显示高血压(OR=1.881,95％CI:1.113～3.181)、糖尿病(OR=1.657,95％CI:1.117～2.457)、颈动脉内粥样斑块(OR=2.208,95％CI:1.285～3.792)均是影响患者疗效的独立危险因素.结论:替罗非班联合尤瑞克林治疗APCI患者疗效显著,可明显改善患者神经缺损症状和预后.
Abstract
Objective:To investigate the effectiveness of tirofiban combined with ureklin in the treatment of patients with acute progressive cerebral infarction(APCI),and to analyze the risk factors that affect the efficacy of patients.Methods:A total of 160 cases of APCI were selected as the research objects and randomly divided into an observation group and a control group,80 cases in each group.The control group was treated with urinary kallidinogenase,and the observation group was treated with tirofiban combined with urinary kallidinogenase.The clinical efficacy,NIHSS score,Barthel score,Mrs score and adverse reactions were compared between the two groups.Univariate analysis and logistic regression analysis were used to analyze the risk factors affecting the curative effect.Results:The effective rate(92.50％vs.81.25％)and good prognosis rate(91.25％vs.80.00％)in the observation group were significantly higher than those in the control group(P＜0.05).After treatment,the NIHSS score in the two groups was significantly reduced,while the Barthel index was significantly in-creased.Among them,the NIHSS score and Barthel index in the observation group were significantly better than those in the control group at the 3rd,7th,and 14th day of treatment(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Univariate and multivariate Logistic regression analysis showed hyper-tension(OR=1.881,95％CI:1.113～3.181),diabetes(OR=1.657,95％CI:i.117～2.457),atherosclerotic plaque in the carotid artery(OR=2.208,95％CI:1.285～3.792)were the independent risk factors that affected the efficacy of patients.Conclusion:Tirofiban combined with ureklin has a significant effect in the treatment of patients with APCI,which can significantly improve neurological deficit symptoms and patient prognosis.
关键词
替罗非班/尤瑞克林/急性进展性脑梗死/神经缺损/危险因素Key words
Tirofiban/Urinary Kallidinogenase/Acute progressive cerebral infarction/Nerve defect/Risk factors引用本文复制引用
基金项目
邢台市重点研发计划项目(2020ZC349)
出版年
2024
NETL
NSTL
万方数据